Study of Safety and Dose Effects of 177Lu-PSMA-617 Treatment for Advanced Prostate Cancer

What this Trial Is About

Researchers are conducting an observational study to evaluate how the dose of radiation delivered by 177Lu-PSMA-617 to prostate tumors and nearby organs may predict treatment response and side effects in men with metastatic prostate cancer. The study focuses on patients with progressive, castration-resistant prostate cancer that overexpresses PSMA and who have previously received chemotherapy and hormone therapy. Data are collected from routine care without changing treatment or management. The treatment involves six standard cycles of 177Lu-PSMA-617 given every six weeks at a fixed dose of 7.4 GBq. Patients are selected based on a PETCT scan that confirms PSMA expression, ensuring the treatment targets the cancer effectively. Dosimetric calculations are done using scintigraphic images taken after each treatment to measure radiation absorbed by tumors and organs. Participants undergo usual care at the nuclear medicine department, where imaging scans and clinical data are collected throughout treatment and follow-up, lasting about 10 months. Researchers analyze total radiation doses in relation to prostate-specific antigen levels, tumor response, and functional assessments to better understand treatment effects and safety. The study collects data from imaging, laboratory results, and monitoring during and after treatment without changing clinical routines.

Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.